119 related articles for article (PubMed ID: 7916903)
1. Modulation of transcription factor--DNA interactions by anticancer drugs.
Broggini M; D'Incalci M
Anticancer Drug Des; 1994 Aug; 9(4):373-87. PubMed ID: 7916903
[TBL] [Abstract][Full Text] [Related]
2. DNA minor groove binders as potential antitumor and antimicrobial agents.
Baraldi PG; Bovero A; Fruttarolo F; Preti D; Tabrizi MA; Pavani MG; Romagnoli R
Med Res Rev; 2004 Jul; 24(4):475-528. PubMed ID: 15170593
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
[TBL] [Abstract][Full Text] [Related]
4. Transcription factors as targets of anticancer drugs.
Gniazdowski M; Czyz M
Acta Biochim Pol; 1999; 46(2):255-62. PubMed ID: 10547027
[TBL] [Abstract][Full Text] [Related]
5. Non-covalent ligand/DNA interactions: minor groove binding agents.
Nelson SM; Ferguson LR; Denny WA
Mutat Res; 2007 Oct; 623(1-2):24-40. PubMed ID: 17507044
[TBL] [Abstract][Full Text] [Related]
6. The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.
Coley HM; Mongelli N; D'Incalci M
Biochem Pharmacol; 1993 Feb; 45(3):619-26. PubMed ID: 8442762
[TBL] [Abstract][Full Text] [Related]
7. Sequence selectivity, cross-linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustards.
McClean S; Costelloe C; Denny WA; Searcey M; Wakelin LP
Anticancer Drug Des; 1999 Jun; 14(3):187-204. PubMed ID: 10500495
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of DNA sequence and minor groove selective alkylating agents.
Lee M; Rhodes AL; Wyatt MD; Forrow S; Hartley JA
Anticancer Drug Des; 1993 Jun; 8(3):173-92. PubMed ID: 8517912
[TBL] [Abstract][Full Text] [Related]
9. Novel DNA-directed alkylating agents consisting of naphthalimide, nitrogen mustard and lexitropsin moieties: synthesis, DNA sequence specificity and biological evaluation.
Gupta R; Liu J; Xie G; Lown JW
Anticancer Drug Des; 1996 Dec; 11(8):581-96. PubMed ID: 9022747
[TBL] [Abstract][Full Text] [Related]
10. Napthalimidobenzamide DB-51630: a novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity.
Suzuki K; Nagasawa H; Uto Y; Sugimoto Y; Noguchi K; Wakida M; Wierzba K; Terada T; Asao T; Yamada Y; Kitazato K; Hori H
Bioorg Med Chem; 2005 Jun; 13(12):4014-21. PubMed ID: 15911314
[TBL] [Abstract][Full Text] [Related]
11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells.
Nagatani G; Nomoto M; Takano H; Ise T; Kato K; Imamura T; Izumi H; Makishima K; Kohno K
Cancer Res; 2001 Feb; 61(4):1592-7. PubMed ID: 11245470
[TBL] [Abstract][Full Text] [Related]
13. Selective binding of small molecules to DNA: application and perspectives.
Wang B; Tan J; Zhu L
Colloids Surf B Biointerfaces; 2010 Aug; 79(1):1-4. PubMed ID: 20447811
[TBL] [Abstract][Full Text] [Related]
14. Minor groove DNA-protein contacts upstream of a tRNA gene detected with a synthetic DNA binding ligand.
McBryant SJ; Baird EE; Trauger JW; Dervan PB; Gottesfeld JM
J Mol Biol; 1999 Mar; 286(4):973-81. PubMed ID: 10047474
[TBL] [Abstract][Full Text] [Related]
15. Bis-benzimidazole anticancer agents: targeting human tumour helicases.
Soderlind KJ; Gorodetsky B; Singh AK; Bachur NR; Miller GG; Lown JW
Anticancer Drug Des; 1999 Feb; 14(1):19-36. PubMed ID: 10363025
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
Zhai X; Beckmann H; Jantzen HM; Essigmann JM
Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
[TBL] [Abstract][Full Text] [Related]
17. DNA sequence recognition by bispyrazinonaphthalimides antitumor agents.
Carrasco C; Joubert A; Tardy C; Maestre N; Cacho M; Braña MF; Bailly C
Biochemistry; 2003 Oct; 42(40):11751-61. PubMed ID: 14529286
[TBL] [Abstract][Full Text] [Related]
18. Structure of the d(CGCGAATTCGCG)2 complex of the minor groove binding alkylating agent alkamin studied by mass spectrometry.
Majid AM; Smythe G; Denny WA; Wakelin LP
Mol Pharmacol; 2007 Apr; 71(4):1165-78. PubMed ID: 17251328
[TBL] [Abstract][Full Text] [Related]
19. Recognition and repair of DNA-cisplatin adducts.
Woźniak K; Błasiak J
Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
[TBL] [Abstract][Full Text] [Related]
20. Distribution of furamidine analogues in tumor cells: targeting of the nucleus or mitochondria depending on the amidine substitution.
Lansiaux A; Tanious F; Mishal Z; Dassonneville L; Kumar A; Stephens CE; Hu Q; Wilson WD; Boykin DW; Bailly C
Cancer Res; 2002 Dec; 62(24):7219-29. PubMed ID: 12499262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
